Prev Close | 243.03 |
Day Low/High | 231.74 / 247.95 |
52 Wk Low/High | 49.03 / 243.97 |
Prev Close | 243.03 |
Day Low/High | 231.74 / 247.95 |
52 Wk Low/High | 49.03 / 243.97 |
Exchange | NYSE |
Shares Outstanding | 11.77B |
Market Cap | 2.86B |
P/E Ratio | 27.68 |
Div & Yield | N.A. (N.A) |
As more Americans struggle with obesity, Medifast sees strength in weight-loss offerings.
Celebrate Thanksgiving with these specially selected picks for your portfolio.
Disney, Qualcomm and Square are among 75 key reports we are watching.
Post's IPO of its star Active Nutrition segment is expected to take place in the December quarter.
Shares of Medifast are in robust shape, up nine percent so far this year, heading into the weight loss provider's second busiest season of the year.
New Year’s resolution season is the busiest time of the year in the weight loss industry.
These companies should feast as more obese Americans turn to exercise and healthy foods.
Medifast finished the first quarter ahead of where it wanted to be and the weight loss company is now gearing up for a strong second half, says CEO Michael MacDonald.
Especially true after the weakness in overseas markets.
Economic data seem to be shifting for the better.
The start of diet season - January through April - looks bright for Medifast so far, says the company's CEO Michael MacDonald, as does Medifast's expansion plans into Canada.
Weight loss stocks have seen turmoil this summer, but Medifast CEO Michael MacDonald says his company will overcome the problems plaguing Herbalife and Weight Watchers.
Medifast CEO Mike MacDonald expects 19% growth in the meal replacement business.
After last Friday's follow-through, the action has been unconvincing.
While these reports should offer clarity, the election will clear a much bigger overhang on the market.
Mike MacDonald, CEO of Medifast, says the company's new franchise strategy is propelling its stock and recently approved weight loss pills are not a threat.
Plenty of activity in the nutritional-supplements industry today.
These under-the-radar stocks have done very well of late, and they have the fundamentals to back it up.